Search for Terms or Answers
Epidemiologic estimates on systemic lupus erythematosus (SLE) diagnosis are limited. The Centers for Disease Control and Prevention (CDC) National Lupus Registry network of population-based SLE registries has assessed and reported age-specific incidence of SLE
A EUVAS-sponsored expert panel of 37 specialists across rheumatology, nephrology, dermatology and pathology has published evidence-based guidelines for adult-onset IgA vasculitis (IgAV), which behaves very differently in adults compared to usually self-limited childhood form.
Read Article
A new study may add fuel to the fire already burning around avacopan (Tavneos), approved in 2021 to treat anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV), which the FDA wants drugmaker Amgen to pull from the U.S. market.
Read Article
This review article addresses the recognition, prevention and management of glucocorticoid toxicity in rheumatic patients.
Read Article
Dr. Cush reviews the news and journal articles from this past week on RheumNow.com; talking about lumbar belts, scholarships and misdiagnosis.
Read Article
The rheumatology and scleroderma communities mourn the loss of Dr. Thomas A. Medsger Jr., who died August 15, 2026, in Pittsburgh, at age 89.
Read Article
Dr. John Cush @RheumNow( View Tweet )
RA confers a 50–100% excess risk of venous thromboembolism (VTE) compared with the general population, with adjusted hazard/odds ratios ranging from 1.3–2.2 across large cohort studies (Vojinovic, Askling, Antovic; Rheumatology, 2026).
Read Article
A current report from the national NHIS survey shows that over half of US adults diagnosed with arthritis reported moderate to severe joint pain.
Read Article
Shoulder pain affects 16% of adults annually and is the third most common musculoskeletal presentation in primary care. This new review reframes the diagnostic and therapeutic approach, moving away from pathoanatomic labels (rotator cuff tendinopathy, impingement, bursitis) toward the umbrella
Read Article
Dr. John Cush @RheumNow( View Tweet )
Today Argenx announced the results of their Phase 3 "ALKIVIA" study; demonstrating efficacy and safety of subcutaneous efgartigimod for Idiopathic Inflammatory Myopathy (IIM, AKA inflammatory myositis).
Read Article
A review article assesses and integrates mechanistic, imaging, and clinical evidence to examine whether effective treatment of psoriasis may modify the future risk of psoriatic arthritis (PsA).
Read Article
Dr. Jack Cush reviews the news and journal articles this week where RheumNow featured info on cancer, deadly viruses, AI rules, poetry and good moons rising.
Read Article
The phase 3 ZEUS trial (published in JAMA Dec. 2025) tested the IL-6 ligand inhibitor ziltivekimab in over 6,000 patients with atherosclerotic cardiovascular disease, chronic kidney disease, and elevated hsCRP—a population enriched for an inflammatory driver of risk.
Read Article
The British Society for Rheumatology has issued its first guideline dedicated solely to pain in inflammatory arthritis (IA)—covering RA, PsA, axial SpA and JIA.
Read Article
Lee, Levinson, and Makris have published an approach to evaluating inflammatory joint pain in older adults in JAMA Internal Medicine. While intended to be a practical guide for primary care clinicians, the tenets and clues ring true for all.
Read Article
Patients from wealthier European countries tend to start treatment with biologics earlier but also stop or switch treatment earlier. They also experience lower disease activity at treatment start than patients in middle- and low-income countries.
Read Article
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
